| | |
| | |
| Clinical data | |
|---|---|
| Other names | LY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H18ClN3 |
| Molar mass | 299.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lergotrile (INN , USAN ; developmental code name LY-79907) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity. [1] [2]
The drug's hydroxylated metabolite 13-hydroxylergotrile is 100-fold more potent as a dopamine receptor agonist than lergotrile itself in vitro . [3] [4]